Drug · DIN 02527618
VABYSMO
SINGLE-USE VIAL
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since July 18, 2022; first marketed July 18, 2022.
- Drug Identification Number (DIN)
- 02527618
- Company (DIN owner)
- Hoffmann-La Roche LimitedMississauga, Ontario, Canada
- Schedule
- Prescription; Schedule D
- Dosage form
- Solution
- Route
- Intravitreal
- Therapeutic class (ATC)
- Faricimab S01LA09
- Class
- Human
- Record last updated
- August 12, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| FARICIMAB | 6 MG | 0.05 ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- May 27, 2022: NOC 28281New Drug Submission (NDS)
Other DINs named VABYSMO
- DIN 02554003 · Marketed